Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, ...

The COVID-19 pandemic highlighted the urgent need for effective therapeutic agents against SARS-CoV-2. Although vaccines ...

The immune molecule TGFβ has been found to weaken immune defences against latent viruses, triggering reactivation of the Epstein–Barr virus. This mechanism links TGFβ release in SARS-CoV-2 ...

Small-molecule inhibitors targeting viral proteins could serve as an effective alternative for controlling the spread of COVID-19 at both individual and community levels. In this vein, a recent study ...

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

SARS-CoV-2, the virus responsible for COVID-19 ... Starting with LCB1, a mutation-sensitive RBD-binding molecule, they developed a 39-amino acid peptide, enhancing its stability, mutation tolerance, ...

Small-molecule inhibitors targeting viral proteins ... explored natural products as potential inhibitors of the SARS-CoV-2 spike protein using computational methods. As described in their paper ...

The COVID-19 pandemic highlighted the urgent need for effective therapeutic agents against SARS-CoV-2. Although vaccines ...

Make the molecule too polar, and it won’t be taken ... and they both contain a nitrile group that reacts with a cysteine in SARS-CoV-2’s Mpro. The Pfizer scientists described ibuzatrelvir ...